How available to biotech start-ups have philanthropic and other sources of soft funding become today?

All of these non-dilutive financing sources are becoming increasingly numerous thanks to both the emergence of interest expressed by many trusts and foundations in financing innovative start-ups, and also to the many governmental schemes that are devoted to financing the first steps
of biotech start-ups. How do these sources of revenue lead to real leverage effect or create constraints for the companies? What types of constraints do they expose biotech
entrepreneurs to?